Ucb S.a.

Ucb Pharma, S.a.

Ucb Farchim Sa

Ucb Biopharma Sprl

Ucbbiopharma Srl

Ucb, Inc.

Domenico Fanara

Michel Deleers

Anthony Guichaux

Monique Berwaer

Frédéric Eeckman

Frederic Eeckman

Guy Bodson

Charles Dogimont

Anne Bouquelle

Jacques Timmermans

Henri Vranckx

Valery Barillaro

Philippe Nolf

Serge Cuypers

Martine Larbanoix

Frederic Dargelas

Frédéric Dargelas

The present invention relates to an immediate release formulation of pharmaceutical compounds.

Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

The present invention relates to a pharmaceutical composition comprising Levetiracetam, Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative

The present invention relates to pharmaceutical compositions for oral administration of active compounds.

Formulations

The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Pharmaceutical compositions comprising Brivaracetam

The present invention relates to a pharmaceutical composition comprising Brivaracetam or Seletracetam as active ingredient, the invention relates specifically to a prolonged release formulation made of granules containing the active ingredient in their inner core.

Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Pharmaceutical compositions comprising brivaracetam

The present invention concerns a tablet comprising two distinct segments. More particularly, the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.

Tablet comprising cetirizine and pseudoephedrine

The invention relates to pharmaceutical compositions which can be administrated orally, allowing the controlled release of at least one active substance comprising

Pharmaceutical compositions for the controlled release of active substances

The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at least one active substance, between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, and mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures including a polyacrylic acid and at least one hydrophilic matrix of the cellulose type; and between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates, phosphates, sodium borate and basic salts of organic acids. The invention further includes a process for preparation of the composition, multi-layered pharmaceutical compositions including at least one layer of the inventive composition, and processes for producing same.

Pharmaceutical compositions for controlled release of active substances

The invention concerns pharmaceutical compositions for oral administration, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and at least a cyclodextrin.

Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin

The present invention relates to new pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;bis (4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride, namely, anhydrous 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride and 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.

Pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;Bis (4-fluorophenyl) methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride

The present invention relates to new pseudopolymorphic forms of 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride, namely, anhydrous 2-&lsqb;2-&lsqb;4-&lsqb;bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride and 2-&lsqb;2-&lsqb;-bis(4-fluorophenyl)methyl&rsqb;-1-piperazinyl&rsqb;ethoxy&rsqb;acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.

Growing community of inventors

Ham-sur-Heure-Nalinnes, Belgium

Monique Berwaer